SESSION 1: TUMOR VACCINES AND OTHER IMMUNOMODULATING STRATEGIES
9:05 am Robert Vanderheide, MD, DPhil
TCE Overview and hTERT DNA Immunotherapy Trial in Adults with Lung Cancer

9:20 am Corey J. Langer, MD
Overview of Clinical Aspects of TCE: Ongoing and Completed Studies at the University of Pennsylvania’s Abramson Cancer Center

9:30 am Charu Aggarwal, MD
Adenoviral Vector Expressing Herpes Thymidine Kinase (AdV-tk) Gene for Patients with Thoracic Malignancies

9:40 am Jarrod D. Predina, MD
Intratumoral Nesadjuvant AdV-tk for Patients with High Risk Resectable Lung Cancer

9:50 am Evan W. Alley, MD, PhD
Emerging Therapies in Malignant Pleural Mesothelioma: Insights from our Multidisciplinary Pleural Tumor Center

10:00 am Coffee Break

SESSION 2: NOVEL APPROACHES AND CHECKPOINT INHIBITORS IN CLINICAL TRIALS
10:10 am Corey J. Langer, MD
Recently Completed Checkpoint Inhibitor Trials in 1st and 2nd Line Non-small Cell Lung Cancer (NSCLC) at the University of Pennsylvania’s Abramson Cancer Center

10:20 am Stephen J. Bagley, MD
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Marker of Outcomes: Insights from our 1st Year’s Experience with Nivolumab in 2nd Line and Beyond in Advaned NSCLC

10:30 am Corey J. Langer, MD (On Behalf of Joshua M. Bauml, MD)
Phase II Study of Pembrolizumab after Curative Intent Treatment for Oligometastatic NSCLC

10:40 am Christine M. Ciunci, MD
Phase II Trial of Consolidation Pembrolizumab after Concurrent Chemotherapy and Proton Re-irradiation for Thoracic Recurrences of NSCLC

10:50 am Guest Speaker: Martin J. Edelman, MD
Chair, Dept. of Hem/Onc, FACC
Current Translational and Clinical Research Initiatives at Fox Chase Cancer Center

SESSION 3: DATA CAPTURE FOR CANCER RESEARCH AND TRANSLATIONAL MEDICINE
11:10 am Christiana W. Davis, MD
(Project/Database Manager of Thoracic Lung TCE) The State of Thoracic TCE Databases: Insights from a Retrospective Analysis of Epidermal Growth Factor Receptor and the Tumor Suppressor TP53 Genes in NSCLC Patients

11:20 am Michael D. Feldman, MD, PhD
Text Information Extraction System (TIES)-A Clinical Document Search Engine that Supports Tissue Ordering and Acquisition, Building of Tissue Microarrays, and Integration with Tissue Banks

SESSION 4: NOVEL BIOMARKERS AND RADILOGIC CORRELATIVES TO PREDICT RESPONSE TO IMMUNOTHERAPY
12:20 pm E. John Wherry, PhD
Emerging Biocorrelatives in Predicting Benefits to Immuno-Oncology Treatment

12:35 pm Alexander Huang, MD
Re-invigoration of Exhausted CD8 T Cells in NSCLC

12:45 pm Erica L. Carpenter, MBA, PhD
Liquid Biopsy for Diagnosis and Monitoring of Lung Cancer

12:55 pm Jeffrey Thompson, MD
The Clinical Utility of a Circulating Tumor DNA Next Generation Sequencing (NGS) Panel of Oncogenic and Tumor Suppressor Genes in NSCLC Patients

SESSION 5: CAR T CELL AND OTHER IMMUNOCONJUGATE TREATMENT STRATEGIES
1:25 pm Jennifer J.D. Morrissette, PhD
Genomic Alterations in Lung Tumors: Mutational Landscape and Translocation Detection by NGS

1:35 pm Andrew R. Haas, MD
Chimeric Antigen Receptor (CAR) T-Cells Targeting Mesothelin for Malignant Pleural Mesothelioma

1:45 pm Charu Aggarwal, MD
CAR T Cells Targeting Mesothelin for Lung Cancer

1:55 pm Corey J. Langer, MD
Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

SESSION 6: OTHER INITIATIVES IN LUNG CANCER
2:05 pm Anil Vachani, MD
Initiatives to Expedite the Evaluation and Treatment of Lung Nodules

2:15 pm Steven M. Albelda, MD
New Oncology Research Alliance between UPenn and Industry

2:25 pm Closing Remarks – Feedback
Corey J. Langer, MD